Comparison between Ovalbumin and Ovalbumin Peptide 323-339 Responses in Allergic Mice: Humoral and Cellular Aspects

Abstract

Ovalbumin (OVA) is widely used in allergy research. OVA peptide 323‐339 has been reported to be responsible for 25–35% of isolated BALB/c mouse T‐cell response to intact OVA. An investigation of whether OVA and OVA 323‐339 molecules can induce equivalent in vivo and in vitro immune responses was conducted. Eight‐week‐old BALB/c mice were randomly divided into three groups: OVA, OVA 323‐339 and saline. On days 0, 7, 14, mice were intraperitoneally injected with 25 μg OVA or OVA 323‐339 absorbed on 300 μg Alum, or saline; on days 21–23, all groups were challenged intranasally with either 20 μl of 1% OVA, 1% OVA 323‐339 or saline. On day 28, after killing, splenocytes were isolated and cultured under the stimulus of each allergen or medium. Evaluated by hematoxylin/eosin and major basic protein immunohistochemical stainings, OVA and OVA 323‐339 induced similar lung inflammation. Interestingly, significant serum total IgE and OVA‐specific IgE were observed in OVA mice when compared to saline control. OVA 323‐339 mice showed higher serum OVA‐specific IgE, OVA 323‐339‐specific IgE, IL‐4 and lower IFN‐γ similar to OVA mice. The proliferative response to OVA was found in cultured splenocytes of both OVA and OVA 323‐339 mice, while the similar proliferative response to OVA 323‐339 was only observed in the splenocytes of OVA 323‐339‐sensitized and challenged mice. Although OVA 323‐339 induced a Th2‐like response in the mouse model as did OVA, OVA 323‐339 has clearly limited immunogenic potency to activate OVA‐sensitized and challenged mice splenocytes, unlike OVA.

Aquoeous Extract of Neem Leaves (Azadirachta Indica) Decrease Expression of Immunoglbulin E (IgE) and Interleukin 4 (IL-4) in Gingiva Tissue of BALB/c Mice Injected by Ovalbumine

“…It also has been shown by research IgE levels in mice exposed ovalbumin. [2][3][4][5] Problems that arise and has not been solved to date is not yet found a cure for allergies with effect minimum side. Therefore, it needs proper handling solutions allergies, with therapies that have minimal side effects.…”

Mannosylated lipopetides as model vaccines for targeting the mannose receptor

“…Here, recombinant OVA O-mannosylation has been shown to be effective in MR targeting [190]. However, in a previous study, the OVA323-339 epitope produced a Th1 response in mice but its immunogenicity was limited compared to the full OVA protein [189] confirming the need for an adjuvant system for small proteins or peptide epitopes as vaccine candidates.…”

“…indicated that in allergenic mice, the OVA323-339 epitope (using 300 µg alum as adjuvant) produced a Th1 response but its immunogenicity was limited compared to the full native OVA protein [189].…”

“…The OVA protein naturally exists as a glycoprotein, however, it was discovered that the OVA [323][324][325][326][327][328][329][330][331][332][333][334][335][336][337][338][339] and OVA 1-10 sequences of the OVA protein bore a B cell epitope that was capable of inducing a T cell response. This discovery was obtained by T cell mediated IgE responses that were observed against an assumed B cell epitope inside OVA323-339 and OVA1-10 peptides [185].…”

“…The OVA323-339 peptide epitope has long been studied for its immune activating properties [189,304].…”